ReviewDrugs2005
Advances in colonic drug delivery.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms.Pharmaceutical research · 2008Trial
- Mesoporous nanomaterial-based smart nanoplatforms for precise therapies of ulcerative colitis: Strategies and challenges.Theranostics · 2025Review
- Advancements in Colon-Targeted Drug Delivery: A Comprehensive Review on Recent Techniques with Emphasis on Hot-Melt Extrusion and 3D Printing Technologies.AAPS PharmSciTech · 2024Review
- Aerogels as Carriers for Oral Administration of Drugs: An Approach towards Colonic Delivery.Pharmaceutics · 2023Review
- Insights into Protective Effects of Different Synbiotic Microcapsules on the Survival ofFoods (Basel, Switzerland) · 2022Article
- Mucoadhesive carriers for oral drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Pathways for Oral and Rectal Delivery of Gold Nanoparticles (1.7 nm) and Gold Nanoclusters into the Colon: Enteric-Coated Capsules and Suppositories.Molecules (Basel, Switzerland) · 2021Article
- Alcohol Use in Patients With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2021Article
- Fabrication of Guar-Only Electrospun Nanofibers by Exploiting a High- and Low-Molecular Weight Blend.ACS omega · 2019Article
- Optimization of Chitosan and Cellulose Acetate Phthalate Controlled Delivery of Methylprednisolone for Treatment of Inflammatory Bowel Disease.Advanced pharmaceutical bulletin · 2017Article
- A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media.International journal of nanomedicine · 2016Article
- Design of Silk-Vaterite Microsphere Systems as Drug Carriers with pH-responsive Release Behavior.Journal of materials chemistry. B · 2015Article
- Stimuli-responsive theragrippers for chemomechanical controlled release.Angewandte Chemie (International ed. in English) · 2014Article
- Assessment of isomalt for colon-specific delivery and its comparison with lactulose.AAPS PharmSciTech · 2013Article
- Formulation Development and Evaluation of Drug Release Kinetics from Colon-Targeted Ibuprofen Tablets Based on Eudragit RL 100-Chitosan Interpolyelectrolyte Complexes.ISRN pharmaceutics · 2013Article
- Shape effect in the design of nanowire-coated microparticles as transepithelial drug delivery devices.ACS nano · 2012Article
- Development of novel budesonide pellets based on CODES(TM) technology: In vitro/in vivo evaluation in induced colitis in rats.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2011Article
- Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol.AAPS PharmSciTech · 2010Article
- Optimization of budesonide compression-coated tablets for colonic delivery.AAPS PharmSciTech · 2009Article
- Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems.Pharmaceutical research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting drugs and delivery systems to the colonic region of the gastrointestinal tract has received considerable interest in recent years. Scientific endeavour in this area has been driven by the need to better treat local disorders of the colon such as inflammatory bowel disease (ulcerative colitis and Crohn's disease), irritable bowel syndrome and carcinoma. The colon is also receiving significant attention as a portal for the entry of drugs into the systemic circulation. A variety of delivery strategies and systems have been proposed for colonic targeting. These generally rely on the exploitation of one or more of the following gastrointestinal features for their functionality: pH, transit time, pressure or microflora. Coated systems that utilise the pH differential in the gastrointestinal tract and prodrugs that rely on colonic bacteria for release have been commercialised. Both approaches have their own inherent limitations. Many systems in development have progressed no further than the bench, while others are expensive or complex to manufacture, or lack the desired site-specificity. The universal polysaccharide systems appear to be the most promising because of their practicality and exploitation of the most distinctive property of the colon, abundant microflora.
Indexed as
Identifiers
16162022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.